Ani Pharmaceuticals (ANIP) Total Non-Current Liabilities (2011 - 2026)

Ani Pharmaceuticals has disclosed Total Non-Current Liabilities across 15 years of filings, most recently posting $851.1 million for Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $851.1 million, up 1.08% year-over-year; the trailing twelve-month figure through Mar 2026 was $851.1 million (up 1.08% YoY), and the FY2025 annual result was $887.5 million, up 4.39% from the prior year.
• Total Non-Current Liabilities came in at $851.1 million for Q1 2026 at Ani Pharmaceuticals, down from $887.5 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $891.0 million in Q3 2025 to a low of $366.7 million in Q1 2022.
• The 5-year median for Total Non-Current Liabilities is $435.5 million (2024), against an average of $594.4 million.
• Across the five-year window, Total Non-Current Liabilities dropped 4.58% in 2022 and jumped 99.51% in 2025, its largest moves.
• Ani Pharmaceuticals' Total Non-Current Liabilities stood at $386.5 million in 2022, then increased by 14.37% to $442.0 million in 2023, then jumped by 92.34% to $850.2 million in 2024, then increased by 4.39% to $887.5 million in 2025, then dropped by 4.1% to $851.1 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $851.1 million (Q1 2026), $887.5 million (Q4 2025), and $891.0 million (Q3 2025), per Business Quant data.